Delving into the Latest Updates on JNJ-525 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

TNF-α

Action

inhibitors

Mechanism

TNF-α inhibitors(Tumor necrosis factor α inhibitors)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Janssen Research & Development LLC

Active Organization-

Inactive Organization

Proteros biostructures GmbHJanssen Research & Development LLC

License Organization-

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

A prevalent observation in high-throughput screening and drug discovery programs is the inhibition of protein function by small-molecule compound aggregation. Here, we present the X-ray structural description of aggregation-based inhibition of a protein-protein interaction involving tumor necrosis factor α (TNFα). An ordered conglomerate of an aggregating small-molecule inhibitor (JNJ525) induces a quaternary structure switch of TNFα that inhibits the protein-protein interaction between TNFα and TNFα receptors. SPD-304 may employ a similar mechanism of inhibition.

100 Deals associated with JNJ-525

Login to view more data